To print: Select File and then Print from your browser's menu

Title: FDA Approves Atazanavir Boosted With Ritonavir for Treatment-Naïve HIV Patients

"FDA Approves Atazanavir Boosted With Ritonavir for Treatment-Naïve HIV Patients"

NEW YORK -- October 2, 2008 -- The US Food and Drug Administration has approved atazanavir sulfate (Reyataz) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in treatment-naïve HIV-1 infected patients. The approval is based on 48-week results from the CASTLE study, which demonstrated similar antiviral efficacy of atazanavir/ritonavir (atazanavir/r) sulfate to twice-daily lopinavir/ritonavir (lopinavir/r), each as part of HIV combination therapy, in treatment- naïve HIV-1 infected adult patients. Within the CASTLE study, the atazanavir/r arm was associated with low increases from baseline in total cholesterol (13%), low-density lipoprotein cholesterol (14%), high-density lipoprotein cholesterol (29%), and triglycerides (15%). Two percent of patients in the atazanavir/r arm and 8% of patients in the lopinavir/r arm required lipid-lowering therapy in the study, compared with 1% in each arm at baseline. Grade 2 to 4 adverse events that occurred in 2% or greater of patients in the CASTLE study included jaundice, nausea, diarrhoea, and rash. Grade 3 to 4 increases in total bilirubin were seen in 34% of patients in the atazanavir/r arm and in less than 1% of patients in the lopinavir/r arm. SOURCE: Bristol-Myers Squibb

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.